Treatment with selumetinib preserves cardiac function and improves survival in cardiomyopathy caused by mutation in the lamin A/C gene

Cardiovascular Research

Volumn 93, Issue 2, 2012, Pages 311-319

  Muchir, Antoine ^a   Reilly, Sarah A ^a,b   Wu, Wei ^a   Iwata, Shinichi ^a   Homma, Shunichi ^a   Bonne, Gisle ^c,d,e   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

^b U974 ^*  (United States)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

A type lamins; Dilated cardiomyopathy; ERK; LMNA; MAP kinase; Selumetinib

Indexed keywords

LAMIN A; LAMIN C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATRIURETIC FACTOR; PLACEBO; RNA; SELUMETINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DETERIORATION; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; GENE MUTATION; HEART; HEART FUNCTION; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAMIN A CARDIOMYOPATHY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SARCOMERE; SURVIVAL;

ANIMALS; BENZIMIDAZOLES; CARDIOMYOPATHY, DILATED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEART; HUMANS; KIDNEY; LAMIN TYPE A; LIVER; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION; PANCREAS;

EID: 84862908072     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr301     Document Type: Article

References (31)

1. Worman HJ, Fong LG, Muchir A, Young SG. Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest 2009;119:1825-1836.
2. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-288. (Pubitemid 29124935)
3. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715-1724.
4. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000;9:1453-1459. (Pubitemid 30312494)
5. Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E et al., Familial Dilated Cardiomyopathy Registry Research Group. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003;41:771-780. (Pubitemid 36308384)
6. Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Peterson A et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 2008;156:161-169.
7. Arbustini E, Pilotto A, Repetto A, Grasso M, Negri A, Diegoli M et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002;39:981-990. (Pubitemid 34234120)
8. Van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med 2005;83:79-83. (Pubitemid 40169500)
9. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52:1250-1260.
10. Stewart CL, Kozlov S, Fong LG, Young SG. Mouse models of the laminopathies. Exp Cell Res 2007;313:2144-2156. (Pubitemid 46842975)
11. Arimura T, Helbling-Leclerc A, Massart C, Varnous S, Niel F, Lacène E et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 2005; 14:155-169. (Pubitemid 40123471)
12. Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimura T, Bonne G et al. Activation of MAPK pathway links LMNA mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. J Clin Invest 2007;117:1282-1293. (Pubitemid 46718416)
13. Muchir A, Shan J, Bonne G, Lehnart SE, Worman HJ. Inhibition of extracellular signalregulate kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins. Hum Mol Genet 2009;18:241-247.
14. Wu W, Shan J, Bonne G, Worman HJ, Muchir A. Pharmacological inhibition of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene. Biochim Biophys Acta 2010;1802:632-638.
15. Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by lamin A/C gene mutation. Circulation 2011;123:53-61.
16. Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hemat Oncol 2010;3:8.
17. Denton CL, Gustafson DL. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol 2010;67: 349-360.
18. Yeh T, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase1/2 inhibitor. Clin Cancer Res 2001;13:1576-1582.
19. Adjei AA, Cohen RB, FranklinW, Morris C, Wilson D, Molina JR et al. Phase I pharmacokinetics and pharmacodynamics study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-2146.
20. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Sae J et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancer. J Clin Oncol 2011;29: 2357-2363.
21. O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcionoma. J Clin Oncol 2011;29:2350-2356.
22. Bhalla S, Gartenhaus R, Dai B, Prachand S, Mukherjee A, Elstrom R et al. The novel 2nd generation small molecule MEK inhibitor, AZD-6244, induces cell death in lymphoma cells lines, primary cells, and in a human lymphoma xenograft model. (Abstract). Blood (ASH Annual Meeting Abstracts) 2009; 114: 285.
23. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003;3:18.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958;53:457-481.
25. Arimura T, Sato R, Machida N, Bando H, Zhan DY, Morimoto S et al. Improvement of left ventricular dysfunction and of survival prognosis of dilated cardiomyopathy by administration of calcium sensitizer SCH00013 in a mouse model. J Am Coll Cardiol 2010; 55:1503-1505.
26. Hutson TE, Bellmunt J, Porta C, Szczylik C, Staehler M, Nadel A et al., TARGET Clinical Trial Group. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46:2432-2440.
27. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J et al. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002;277:38988-38997. (Pubitemid 35154765)
28. Huang H, Petkova SB, Pestell RG, Bouzahzah B, Chan J, Magazine H et al. Trypanosoma cruzi infection (Chagas' disease) of mice causes activation of the mitogen-activated protein kinase cascade and expression of endothelin-1 in the myocardium. J Cardiovasc Pharmacol 2000;36:S148-S150.
29. Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 2011;121: 1009-1025.
30. Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Gwathmey J et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-677. (Pubitemid 32144195)
31. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008;118:84-95.